Abstract:Background Spinal Muscular Atrophy (SMA) is a progressive degenerative neuromuscular disease that can cause several motor, respiratory, and functional impairments, directly interfering with the quality of life (QoL). Depending on the severity of the SMA, the individual may need intermittent care and their caregivers may feel overwhelmed with this responsibility. Objectives To correlate caregiver burden and motor function measurement (MFM) of individuals with SMA with their QoL. Methods Descriptive cross-sectional study, carried out in a state rehabilitation center in Goiânia, Goiás, Brazil. Data collection was carried out from March to July 2022, consisting of individuals diagnosed with SMA types I, II, and III being followed up at the institution's Neuromuscular Diseases Clinic and their main family caregivers. To analyze the MFM, participants younger than six years old were evaluated using the Motor Function Measurement Scale - Short Version (MFM-20), and those older than six years old using the Motor Function Measurement Scale (MFM-32). For QoL assessment, those over five years old answered the PedsQL Neuromuscular 3.0 questionnaire according to age group, while those under five years old had the same questionnaire answered by their guardians. To assess caregiver burden, the Burden Interview questionnaire was used. The distribution of demographic profile and clinical data was tested according to the type of SMA by applying Pearson's Chi-square test and “Post hoc” standardized residual analysis. The QoL, MFM, and caregiver burden were tested between the types of EBF using the Analysis of Covariance (ANCOVA), controlling the effect of variables that presented p < 0.05 in the initial exploratory analyses. The significance level adopted was p < 0.05. Results The sample consisted of 32 individuals with SMA, 6(18.7%) type I, 9(28.1%) type II, and 17(53.1%) type III, with a mean age of 21.9± 17.3 years old, mostly male 17(53.1%) and 27 caregivers, 26(96.3%) females. The MFM showed a moderate positive correlation with the QoL of individuals with SMA type II (r = 0.71; p = 0.05) and in type III it had a strong positive correlation with statistical significance (r = 0.63; p = 0. 01). Caregiver burden had a negative correlation with QoL in SMA types II and III (r = - 0.71; p = 0.05 and r = -0.16; p = 0.63, respectively), without statistical significance. Conclusion MFM correlated with the QoL of individuals with SMA, especially type III. The burden of caregivers showed a negative relationship with the QoL of people with SMA, highlighting the need for care for this population. Implications Knowledge of the motor function of individuals with SMA and the burden of their caregivers are important aspects that allow for more specific therapeutic approaches according to their individualities.

Experiences and the psychosocial situation of parental caregivers of children with spinal muscular atrophy against the background of new treatment options: a qualitative interview study

Parents as informal caregivers of children and adolescents with spinal muscular atrophy: a systematic review of quantitative and qualitative data on the psychosocial situation, caregiver burden, and family needs

Quality of Life of Children with Spinal Muscular Atrophy and Their Caregivers from the Perspective of Caregivers: a Chinese Cross-Sectional Study

Treatment preferences in spinal muscular atrophy: A swing weighting study for caregivers of patients with SMA types 1 and 2

Use of the Assessment of Caregiver Experience with Neuromuscular Disease (ACEND) in Spinal Muscular Atrophy

Areas of improvement in the medical care of SMA: evidence from a nationwide patient registry in Germany

Parental experiences and coping strategies when caring for a child receiving paediatric palliative care: a qualitative study

Spinal Muscular Atrophy Update in Best Practices: Recommendations for Treatment Considerations

Identification of the most relevant aspects of spinal muscular atrophy (SMA) with impact on the quality of life of SMA patients and their caregivers: the PROfuture project, a qualitative study

Life-Saving Treatments for Spinal Muscular Atrophy: Global Access and Availability

Lifesaving Treatments for Spinal Muscular Atrophy: Global Access and Availability

Treatment Options in Spinal Muscular Atrophy: A Pragmatic Approach for Clinicians

Evaluation of a Case Management to Support Families With Children Diagnosed With Spinal Muscular Atrophy-Protocol of a Controlled Mixed-Methods Study

Understanding the impact of pediatric single large‐scale mtDNA deletion syndromes on caregivers: Burdens and challenges

Prenusinersen economic and health-related quality of life burden of spinal muscular atrophy

IMPACT OF MOTOR FUNCTION OF INDIVIDUALS WITH SPINAL MUSCULAR AMYOTROPHY AND OVERLOAD OF THEIR CAREGIVERS ON QUALITY OF LIFE

Spinal presentations in children with spinal muscular atrophy type 1 following gene therapy treatment with onasemnogene abeparvovec - The SMA REACH UK network experience

“I have SMA, SMA doesn’t have me”: a qualitative snapshot into the challenges, successes, and quality of life of adolescents and young adults with SMA

Measuring Outcomes in Adults with Spinal Muscular Atrophy - Challenges and Future Directions - Meeting Report

Feasibility and utility of in-home body weight support harness system use in young children treated for spinal muscular atrophy: A single-arm prospective cohort study

Advances and limitations for the treatment of spinal muscular atrophy